CareLit · DOI-Nachweis · Diabetologie und Stoffwechsel
Liraglutide 3.0 mg for weight management in obese/overweight adults with Type 2 Diabetes: Results from the SCALE diabetes 56-week randomized, double-blind, placebo-controlled trial
DOI 10.1055/s-0035-1556576
Bibliografische Angaben
Nachweis in CareLit
Autor:innenM Davies, B Bode, R Kushner, A Lewin, T Vang Skjøth, CB Jensen, R De Fronzo, J Kienhöfer, A Pfeiffer
ZeitschriftDiabetologie und Stoffwechsel
Ausgabe08/2015
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Liraglutide at doses up to 1.8 mg in combination with OADs and/or basal insulin is approved for the treatment of T2D. The randomized, double-blind, placebo-controlled trial SCALE Diabetes (NCT01272232) investigated the efficacy and safety of liraglutide 3.0 mg, as adjunct to diet and exercise, for weight management in obese/overweight adults with T2D. 846 individuals (age 54.9 years, M/F 50:50, BMI 37.1 kg/m2 [27.0…
Zitieren
Zitierempfehlung
M Davies, B Bode, R Kushner, A Lewin, T Vang Skjøth, CB Jensen, R De Fronzo, J Kienhöfer, A Pfeiffer (2015) Liraglutide 3.0 mg for weight management in obese/overweight adults with Type 2 Diabetes: Results from the SCALE diabetes 56-week randomized, double-blind, placebo-controlled trial. Diabetologie und Stoffwechsel (08). https://doi.org/10.1055/s-0035-1556576
Mit CareLit weiterarbeiten